

In the Specification:

Please enter the Sequence Listing attached hereto.

Please replace the paragraph that begins on page 13, line 21 and ends on page 13, line 29 with the following paragraph.

An oligonucleotide (SEQ ID NO:1, 3'-CTAGTCTGTGAAGTGTCTGATC-5', 22-mers) having an amino group at 3'-terminal and a fluorescent label (FluoroLink, Cy 5-Dctp, available from Amasham Pharmacia Biotec Corp.) at 5'-terminal was treated with 5-hexynoic acid (available from Tokyo Kasei Industries Co., Ltd.) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (available from Tokyo Kasei Industries Co., Ltd.) to incorporate a 5-heptynoylamino group into the 3'-terminal of the oligonucleotide.

Please replace the paragraph that begins on page 14, line 25 and ends on page 14, line 36 with the following paragraph.

A target oligonucleotide (SEQ ID NO:2, GATCAGACACTTCACAGACTAG-5', 22-mers) having Cy5 (fluorescent label) at its 5'-terminal was dispersed in 20 μ L of a hybridizing solution (mixture of 4 x SSC and 10 wt.% SDS). The resulting solution was spotted onto the glass plate (D2) prepared in (1) above, and its spotted surface was covered with a covering glass. Thus covered chip was subjected to incubation at 60°C for 20 hours in a moisture chamber. The incubated chip was washed successively with a mixture of 0.1 wt.% SDS and 2Xssc, a mixture of 0.1 wt.% SDS and 0.2Xssc, and an aqueous 0.2Xssc solution, centrifuged at 600 r.p.m. for 20 seconds, and dried at room temperature.

STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME

The undersigned hereby states that each computer readable form of the sequence listing submitted herewith is the same as the "Sequence Listing" to which it is indicated to relate. It is submitted that no new matter has been entered in the sequence listing embodied in the attached substitute sheets and the computer readable disk.